Contents of volume 21

No. 1 (pp 1– 88) published February 18, 1988
No. 2 (pp 89–178) published March 24, 1988
No. 3 (pp 179–268) published April 28, 1988
No. 4 (pp 269–356) published May 26, 1988

Aamdal S, Fodstad Ø, Pihl A: Sodium thiosulfate fails to increase the therapeutic index of intravenously administered *cis*-diamminedichloroplatinum (II) in mice bearing murine and human tumors 129
Aarsaether N → Svardal AM, et al. 313
Aarsland A → Svardal AM, et al. 313
Alberts DS → Xu MJ 191
Ameglio F → Pollera CF, et al. 61
Angelelli B → Camaggi CM, et al. 221
Anthony LB → Harris NL, et al. 323
Avramis VI → Powell WC 117

Bagatella M → Giaccone G, et al. 65
Bailey CC → Choonara IA, et al. 173
Banks A → Diehl LF, et al. 347
Bankusli I → Radel S, et al. 25
Berge RK → Svardal AM, et al. 313
Bergers JJ → Steerenberg PA, et al. 299
Bernal SD → Teicher BA, et al. 281
Bertetto O → Giaccone G, et al. 65
Bessell EM → Price P, et al. 265
Bevere F → Pollera CF, et al. 61
Bibby MC → Phillips RM, et al. 168
Bird MC → Bosanquet AG 211
Bishop JAM → Speth PAJ, et al. 343
Blackledge GRP → Stuart NSA, et al. 351
Bloom HJG → Price P, et al. 265
Bokkel Huinink WW ten → Elferink F, et al. 57
Bonna RL → Elliot GT, et al. 233
Booth F → Littlewood TJ, et al. 175
Bosanquet AG, Bird MC: Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays 211
Bose R, Lam H-Y-P: Membrane transport changes in an adriamycin-resistant murine leukemia cell line and in its sensitive parental cell line 14
Bout B → Smets LA, et al. 9
Boxall FE → Siddik ZH, et al. 19
Brasch H → Iven H 337
Brenner DE → Harris NL, et al. 323
Brodfuehrer JI → Moore DJ, et al. 269
Brown GW → Speth PAJ, et al. 343
Burke TG, Sartorelli AC, Tritton TR: Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group 274
Burns ER → Elliot GT, et al. 233
Burtin C → Eschalier A, et al. 246

Cadman EC → Rochlitz CF, et al. 319
Calciati A → Giaccone G, et al. 65
Camaggi CM, Comparsi R, Strocchi E, Testoni F, Pannuti F: HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids 216
Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F: Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study 221
Cantwell BMJ, Carmichael J, Ghani S, Harris AL: A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma 49
Cantwell BMJ → Veale D, et al. 53
Carmichael J → Cantwell BMJ, et al. 49
Carsana R → Formelli F, et al. 329
Carter W → Diehl LF, et al. 347
Cathcart KNS → Teicher BA, et al. 281
Cathcart KNS → Teicher BA, et al. 286
Chan TK → Liang R, et al. 68
Chapuy E → Eschalier A, et al. 246
Choonara IA, Kendall-Smith S, Bailey CC: Accidental actinomycin D overdosage in man, a case report 173
Cinollo G, Dini G, Franchini E, Lanino E, Sindaco F, Garaventa A: Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin 85
Claessen A → Steerenberg PA, et al. 299
Clark GM → Scheithauer W, et al. 31
Clerici M → Sørensen JB, et al. 89
Cleris L → Formelli F, et al. 329
Collins JC → Harris NL, et al. 323
Comparsi R → Camaggi CM, et al. 216
Comparsi R → Camaggi CM, et al. 221
Coombes RC → Vincent MD, et al. 255
Cox G → Gillies H, et al. 261
Cozzo L → Pollera CF, et al. 61
Creaven PJ, Zakrzewski SF, Greco WR, Madajewicz S, Mittelman A, Pontes JE, Karakousis C, Takita H, Proefrock A: Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate 122
Cullen MH → Stuart NSA, et al. 351

Damon LE → Rochlitz CF, et al. 319
Daugaard G, Rossing N, Rørth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose 163
Daugherty JP, Simpson TA Jr, Mullins DW Jr: Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly (ADP-ribose) polymerase activity in L1210 cells 229
Deeb G → Gaver RC, et al. 197
Diasio RB → Schuetz JD, et al. 208
Diehl LF, Banks A, Carter W, Klein MA, Muss HB, Weiss RB: Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature 347
Dini G → Cinollo G, et al. 85
Donadio M → Giaccone G, et al. 65
Double JA → Phillips RM, et al. 168
Dubbelman R → Elferink F, et al. 57
Duncan GF → Gaver RC, et al. 197

Eguchi K → Shinkai T, et al. 203
Elferink F, Vijgh van der WJF, Klein I, ten Bokkel Huinink WW, Dubbelman R, Mc Vie JG: Pharmacokinetics of carboplatin after intraperitoneal administration 57
Elliot GT, Kelly KF, Bonna RL, Wardlaw TR, Burns ER: In vitro antiproliferative activity of 2'-(2-hydroxyphenyl)-2'-thiazoline-4'-carboxylic acid and its methyl ester on L1210 and P388 murine neoplasms 233
Ellis WJ → Speth PAJ, et al. 343
Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M: Study of histamine release induced by acute administration of antitumor agents in dogs 246
Evans B → Vincent M, et al. 45

Farmen RH → Gaver RC, et al. 197
Faulkner HC → Gaver RC, et al. 197
Feindel W → Panasci L, et al. 143
Feldman S → Sullivan MP, et al. 78
Feun LG → Lu K, et al. 139
Fodstad Ø → Aamdal S, et al. 129
Fogh K → Schrøder H 145
Fogh K → Schrøder H, et al. 150

Formelli F, Cleris L, Carsana R: Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors 329
Fournier C, Vennin P, Hecquet B: Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans 75
Franchini E → Cinollo G, et al. 85
Franken MAM → Steerenberg PA, et al. 299
Frederiksen S → Svendsen KR, et al. 35
Frei EE III → Teicher BA 292

Gál F → K alovánszky J, et al. 40
Garaventa A → Cinollo G, et al. 85
Gaver RC, George AM, Duncan GF, Morris AD, Deeb G, Faulkner HC, Farmen RH: The disposition of carboplatin in the beagle dog 197
Geddes A → Rochlitz CF, et al. 319
George AM → Gaver RC, et al. 197
Ghani S → Cantwell BMJ, et al. 49
Giaccone G, Bagatella M, Bertetto O, Donadio M, Calciati A: Phase II study of divided-dose vinblastine in advanced breast cancer patients 65
Gianni L → Pratesi G, et al. 237
Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S: Phase II trial of idarubicin in patients with advanced lymphoma 261
Giraldi T → Sava G, et al. 241
Gore ME → Speth PAJ, et al. 343
Greco WR → Creaven PJ, et al. 122
Green JA → Speth PAJ, et al. 343
Green JA: In response to Vriesendorp et al.: Prediction of normal tissue damage by cancer chemotherapy 355
Greig NH, Sweeney DJ, Rapoport SI: Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat 1
Griggs JV → Speth PAJ, et al. 343
Groot G de → Steerenberg PA, et al. 299
Gumbrell LA → Speth PAJ, et al. 343

Halter S → Harris NL, et al. 323
Hande KR → Harris NL, et al. 323
Hansen HH → Sørensen JB, et al. 89
Hansen HH → Sørensen 103
Harper P → Gillies H, et al. 261
Harrap KR → Siddik ZH, et al. 19
Harris AL → Cantwell BMJ, et al. 49
Harris AL → Veale D, et al. 53
Harris NL, Brenner DE, Anthony LB, Collins JC, Halter S, Hande KR: The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits 323
Hecquet B → Fournier C, et al. 75
Herlin T → Schrøder H, et al. 150
Herman TS → Teicher BA, et al. 286
Hoesel QGCM van → Steerenberg PA, et al. 299
Holden SA → Teicher BA, et al. 281
Holden SA → Teicher BA, et al. 286
Hong W-S → Shinkai T, et al. 203

Imura N → Satoh M, et al. 176
Inaba M → Ozawa S, et al. 185
Iven H, Brasch H: The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits 337

Johnson S → Gillies H, et al. 261
Jones M → Siddik ZH, et al. 19
Jong WH de → Steerenberg PA, et al. 299

Karakousis C → Creaven PJ, et al. 122
Kelly KF → Elliot GT, et al. 233
Kendall-Smith S → Choonara IA, et al. 173
Kerpel-Fronius S → Kralovánszky J, et al. 40
Kerr N → Veale D, et al. 53
Kiss F → Kralovánszky J, et al. 40
Klein I → Elferink F, et al. 57
Klein MA → Diehl LF, et al. 347
Kobayashi T → Ozawa S, et al. 185
Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F: Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP) 40

Lam H-Y-P → Bose R 14
Lanino E → Cinollo G, et al. 85
Lassiani L → Sava G, et al. 241
Lavarenne J → Eschalier A, et al. 246
Liang R, Chan TK, Todd D: Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime 68
Liang R → Gillies H, et al. 261
Linssen PCM → Speth PAJ, et al. 343
Littlewood TJ, Lydon APM, Booth F: Intraarticular and intraperitoneal administration of etoposide in haematological malignancy 175
Lønning PE → Svardal AM, et al. 313
Loos U → Osterheld HKO, et al. 156
Loo TL → Lu K, et al. 139
Lu K, McLean MA, Vestal ML, Newman RA: Pharmacokinetics of Amonafide in dogs 134
Lu K, Savaraj N, Feun LG, Zhengang G, Umsawasdi T, Loo TL: Pharmacokinetics of homoharringtonine in dogs 139
Lydon APM → Littlewood TJ, et al. 175

Madajewicz S → Creaven PJ, et al. 122
Manzotti C → Pratesi G, et al. 237
Mariani M → Supino R, et al. 251
Marolla P → Pollera CF, et al. 61
Matsushita M → Tsuruo T, et al. 71
Matsuzaki T → Tsuruo T, et al. 71
Matsuzaki T, Yokokura T, Mutai M, Tsuruo T: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice 308
Mayhew E → Radel S, et al. 25
McElwain TJ → Vincent MD, et al. 255
McLean MA → Lu K, et al. 134
McQuillan A → Panasci L, et al. 143
Mc Vie JG → Elferink F, et al. 57
McVie JG → Speth PAJ, et al. 343
Miller A → Speth PAJ, et al. 343
Mitsuhashi Y → Ozawa S, et al. 185
Mittelman A → Creaven PJ, et al. 122
Monfardini S: Presidential address at the European Society for Medical Oncology, Nice, 30 November 1986 179
Moore DJ, Brodfuehrer JI, Wilke TJ, Powis G: Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog 269
Morris AD → Gaver RC, et al. 197
Moyer MP → Scheithauer W, et al. 31
Mühlenbruch BJ → Osterheld HKO, et al. 156
Mulder PHM de → Speth PAJ, et al. 343
Mullins DW Jr → Daugherty JP, et al. 229
Musch E → Osterheld HKO, et al. 156
Muss HB → Diehl LF, et al. 347
Mutai M → Matsuzaki T, et al. 308

Naganuma A → Satoh M, et al. 176
Nakagawa K → Shinkai T, et al. 203
Nakajima T → Shinkai T, et al. 203
Nakano H → Shinkai T, et al. 203
Nardi M → Pollera CF, et al. 61
Nelson JA → Sullivan MP, et al. 78
Newell DR → Speth PAJ, et al. 343
Newman RA → Lu K, et al. 134

Osterheld HKO, Musch E, Unruh GE von, Loos U, Rauschecker H, Mühlenbruch BJ: A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis prodcuts in blood and plasma 156
Overgaard-Hansen K → Svendsen KR, et al. 35
Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M: Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration – time product 185

Panasci L, McQuillan A, Feindel W: The cytolytic effect of L-2,4 diaminobutyric acid with malignant glioma cells and fibroblasts 143
Pannuti F → Camaggi CM, et al. 216
Pannuti F → Camaggi CM, et al. 221
Parapia L → Gillies H, et al. 261
Parmiani G → Supino R, et al. 251
Pateman AJ → Speth PAJ, et al. 343
Pauw BE de → Speth PAJ, et al. 343
Perissin L → Sava G, et al. 241
Phillips RM, Bibby MC, Double JA: Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours 168
Pihl A → Aamdal S, et al. 129
Pollera CF, Marolla P, Nardi M, Ameglio F, Cozzo L, Bevere F: Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects 61
Pontes JE → Creaven PJ, et al. 122
Powell WC, Avramis VI: Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice 117
Powis G → Moore DJ, et al. 269
Powles TJ → Vincent MD, et al. 255
Prajda N → Kralovánszky J, et al. 40
Pratesi G, Gianni L, Manzotti C, Zunino F: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and *cis*-diamminedichloroplatinum combination on primary colon tumors in mice 237
Price P, Thompson H, Bessell EM, Bloom HJG: Renal impairment following the combined use of high-dose methotrexate and procarbazine 265
Priestman TJ → Stuart NSA, et al. 351
Proefrock A → Creaven PJ, et al. 122
Prosperi E → Supino R, et al. 251

Radel S, Bankusli I, Mayhew E, Rustum YM: The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo 25
Rapoport SI → Greig NH, et al. 1
Rauschecker H → Osterheld HKO, et al. 156
Refsum H → Svardal AM, et al. 313
Renoux M → Eschalier A, et al. 246
Rochlitz CF, Damon LE, Russi MB, Geddes A, Cadman EC: Cytotoxicity of ketoconazole in malignant cell lines 319
Rodriguez M → Eschalier A, et al. 246
Rogers H → Gillies H, et al. 261
Rørth M → Daugaard G, et al. 163
Rossing N → Daugaard G, et al. 163
Russi MB → Rochlitz CF, et al. 319
Rustum YM → Radel S, et al. 25

Saijo N → Shinkai T, et al. 203
Saito H → Tsuruo T, et al. 71
Sakurai M → Shinkai T, et al. 203
Sartorelli AC → Burke TG, et al. 274
Sasaki Y → Shinkai T, et al. 203
Satoh M, Naganuma A, Imura N: Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination 176
Sava G, Zorzet S, Perissin L, Giraldi T, Lassiani L: Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes 241
Savaraj N → Lu K, et al. 139
Scheithauer W, Moyer MP, Clark GM, Von Hoff DD: Application of a new preclinical drug screening system for cancer of the large bowel 31
Schrøder H, Fogh K: Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia 145
Schrøder H, Fogh K, Herlin T: In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes 150
Schuetz JD, Wallace HJ, Diasio RB: DNA repair following incorporation of 5-fluorouracil into DNA of mouse bone marrow cells 208
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Suga J, Nakano H, Nakagawa K, Hong W-S, Nakajima T: Cytogenetic effect of carboplatin on human lymphocytes 203
Siddik ZH, Jones M, Boxall FE, Harrap KR: Comparative distribution and excretion of carboplatin and cisplatin in mice 19
Simpson TA Jr → Daugherty JP, et al. 229
Sindaco F → Cinollo G, et al. 85
Smets LA, Bout B, Wisse J: Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG) 9
Smith I → Vincent M, et al. 45
Smith IE → Speth PAJ, et al. 343
Sørensen JB, Clerici M, Hansen HH: Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review 89
Sørensen JB, Hansen HH: Combination chemotherapy for advanced adenocarcinoma of the lung. A review 103
Speth PAJ, Gore ME, Pateman AJ, Newell DR, Bishop JAM, Ellis WJ, Green JA, Gumbrell LA, Linssen PCM, Miller A, Smith IE, McVie JG, Mulder PHM de, Pauw BE de, Griggs JV, Brown GW: Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone 343
Steerenberg PA, Storm G, Groot G de, Claessen A, Bergers JJ, Franken MAM, Hoesel QGCM van, Wubs KL, Jong WH de: Liposomes as drug carrier system for *cis*-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution 299
Storm G → Steerenberg PA, et al. 299
Strocchi E → Camaggi CM, et al. 216
Strocchi E → Camaggi CM, et al. 221
Stuart NSA, Cullen MH, Priestman TJ, Blackledge GRP, Tyrrell CJ: A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer 351
Suga J → Shinkai T, et al. 203
Sugiyama Y → Ozawa S, et al. 185
Sullivan MP, Nelson JA, Feldman S, Van Nguyen B: Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children 78
Supino R, Mariani M, Prosperi E, Parmiani G: Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin 251
Svardal AM, Ueland PM, Berge RK, Aarsland A, Aarsaether N, Lønning PE, Refsum H: Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet 313
Svendsen KR, Overgaard-Hansen K, Frederiksen S: Synergistic effect of 3'-deoxy-adenosine N^1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo 35
Sweeney DJ → Greig NH, et al. 1

Takita H → Creaven PJ, et al. 122
Tamura T → Shinkai T, et al. 203
Teicher BA, Bernal SD, Holden SA, Cathcart KNS: Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity 281
Teicher BA, Herman TS, Holden SA, Cathcart KNS: The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo 286

Teicher BA, Frei E III: Development of alkylating agent-resistant human tumor cell lines 292
Testoni F → Camaggi CM, et al. 216
Testoni F → Camaggi CM, et al. 221
Thompson H → Price P, et al. 265
Todd D → Liang R, et al. 68
Tritton TR → Burke TG, et al. 274
Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo 71
Tsuruo T → Matsuzaki T, et al. 308
Tyrell CJ → Stuart NSA, et al. 351

Ueland PM → Svardal AM, et al. 313
Umsawasdi T → Lu K, et al. 139
Unruh GE von → Osterheld HKO, et al. 156
Upfold A → Veale D, et al. 53

Van Nguyen B → Sullivan MP, et al. 78
Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL: Phase 1 study of high-dose hydroxyurea in lung cancer 53
Vennin P → Fournier C, et al. 75
Vestal ML → Lu K, et al. 134
Vijgh van der WJF → Elferink F, et al. 57
Vincent M, Evans B, Smith I: First-line chemotherapy rechallenge after relapse in small cell lung cancer 45
Vincent MD, Powles TJ, Coombes RC, McElwain TJ: Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy 255
Von Hoff DD → Scheithauer W, et al. 31

Wallace HJ → Schuetz JD, et al. 208
Wardlaw TR → Elliot GT, et al. 233
Weiss RB → Diehl LF, et al. 347
Wilke TJ → Moore DJ, et al. 269
Wisse J → Smets LA, et al. 9
Wubs KL → Steerenberg PA, et al. 299

Xu MJ, Alberts DS: Potentiation of platinum analogue cytotoxicity by hyperthermia 191

Yokokura T → Tsuruo T, et al. 71
Yokokura T → Matsuzaki T, et al. 308

Zakrzewski SF → Creaven PJ, et al. 122
Zhengang G → Lu K, et al. 139
Zorzet S → Sava G, et al. 241
Zunino F → Pratesi G, et al. 237

Indexed in *Current Contents*

Subject index of volume 21

Actinomycin D 173
Acute non-lymphoblastic leukemia 68
Adenocarcinoma of the lung 89, 103
Adenosine 35
Adriamycin 176
Adriamycin resistance 14
Advanced breast cancer 255, 351
Alkylating agents 292
Amonafide 134
Amsacrine 68
Anthracycline 274
Antibiotics 337
Antitumor agent 185, 246
Antitumor effect 241
Ascites 35

BCNU 281
B16-melanoma 251
Bone marrow cells 208
Brain 1
Breast cancer 65
—, advanced 255, 351

Camptothecin 71, 308
Carboplatin 19,57, 197, 203
Cell killing action 185
Chelator 233
Chemosensitivity 168 211
Children 78, 145
Chemotherapy 45, 89, 103, 355
Chlorambucil 1
Cisplatin 19, 61, 75,176
Colon tumors 237
Colorectal cancer 31
Concentration-time product 185
CPT-11 308
Creatinine 163
Creatinine clearance 163
Cyclophosphamide 286
Cytogenic effect 203
Cytolysis 143
Cytotoxicity 25, 191, 319
Cytoxan 286

DAMP-ES 122
Deaminase 35
L-2,4-Diaminobutyric acid 143
cis-Diamminedichloroplatinum 85, 237
cis-Diamminedichloroplatinum (II) 129, 281, 299
Diets 313
Dimethyltriazenes 241
Dog 134, 139, 269
DON 78
Doxorubicin 49, 216, 221, 229, 323, 329
4'-deoxy-4'-iodo-Doxirubicin 251
Drug carrier 299
Drug cross-resistance 251
Drug interaction 337
Drug resistance 25, 299
Drug screening 31

Epirubicin 216, 221
Erythrocyte 145, 150
Esorubicin-induced cardiomyopathy 347
Etoposide 175, 281

Fibroblasts 143
Fibrosarcoma 281
5-Fluorouracil (5-FU) 208, 237
Fluosol-DA 281, 286

Glioma cells 143
GFR 163

Haematological malignancy 175
Hemolytic anaemia 85
Hepatic metabolism 241
High-dose 61
High-dose hydroxyurea 53
High-dose melphalan 255
Histamine release 246
Homocysteine 313
Homoharringtonine 139
Human tumor 129, 292
Hydrolysis product 156
Hydroxyurea, high-dose 53
Hyperbaric oxigen 286
Hypomethylation 117

Idarubicin 261, 351
Ifosfamide 49
Intestinal side effects 40

Ketoconazole 319

L1210 (cells) 117, 229, 233
Leukemia 25
Liposomes 299
Lung cancer 53
Lymphoblastic leukemia 145, 150
Lymphoma 261

Medical oncology 179
Melphalan 156
—, high-dose 255
—, in vitro 211
Metabolism 216, 221
Metallothionein 176
Metastasis 308
Methotrexate 145, 150, 313, 337
Methotrexate toxicity 265
MIBG 9
Mitoquidone 343
Mouse 269
Murine colon tumors 168
Murine leukemia cell line 14

Nephrotoxicity 299
Norepinephrine analogue 9

Ototoxicity 61
Overdose 173

Perfusion therapy 156
Pharmacodynamics 185
Pharmacokinetics 1, 57, 78, 134, 139, 197, 221, 269, 323, 329, 343
Pharmacology 117
Phase I/pharmacokinetics 122
Phase I study 343
Plasma 1
Platinum analogues 191
Platinum complexes 19, 40
P388 murine neoplasm 233
Procarbazine 265
Proteinuria 165
Pyrazine-2-diazohydroxide 269

Ranitidine 323
Renal elimination 337

Sarcoma 49
Sister chromatic exchange 203
Small cell lung cancer 45
Solid tumor 281
Sulfur compounds 313

Thiosulfate 129
ThioTEPA 168
Toxicity 176, 237, 323
Tumors 35, 71
-, solid 281

Verapamile 329
Vinblastine 65